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Benzbromarone, a uricosuric drug, reportedly causes hepatic hypertrophy accompanied by proliferation of peroxisomes in rats.
To elucidate the mechanisms underlying induction of peroxisome proliferation by benzbromarone, we examined binding aﬃnity
for peroxisome proliferator-activated receptor α (PPARα)a n dγ (PPARγ), and eﬀects on the binding activity of PPARs with peroxi-
some proliferation-responsive element (PPRE) and expression of the PPARs target protein. Binding aﬃnity of benzbromarone for
PPARα and PPARγ was examined by reporter gene assay. Binding activity of PPARs with PPRE was determined by electric mobility
shift assay, and expression of lipoprotein lipase (LPL) and acyl-CoA synthetase (ACS) by Western blot method. Benzbromarone
displayed aﬃnity for PPARα and PPARγ, and promoted binding of PPARs to PPRE. Furthermore, cultured cells with benzbro-
marone added showed upregulated expression of LPL and ACS. These results suggest that benzbromarone induces peroxisome
proliferation in hepatocytes by binding to PPARs, and controls expression of proteins related to lipid metabolism.
Copyright © 2007 Chiyoko Kunishima et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Benzbromarone is a uricosuric drug that has been widely
used for more than 25 years as a therapeutic agent for
hyperuricemia. Recently, urate transporter 1 (URAT1) was
identiﬁed in the luminal membrane of the proximal re-
nal tubule, and the mechanism of action for benzbro-
marone was identiﬁed as suppression of uric acid resorp-
tion via inhibition of URAT1 [1]. Regarding the toxic-
ity of benzbromarone, hypertrophy of the liver accompa-
nied by proliferation of peroxisomes has been reported in
a repeated-dose toxicity study in rats [2]. Similar changes
have also been observed in studies on cloﬁbrate and fenoﬁ-
brate, both of which are antihyperlipemic drugs [2, 3].
Cloﬁbrate and fenoﬁbrate represent activators of peroxisome
proliferator-activated receptor α (PPARα), and benzbro-
marone may similarly cause hypertrophy of the liver via ac-
tions on PPARα.
We have previously demonstrated that benzbromarone
has aﬃnity for PPARα and PPARγ, and upregulates expres-
sion of each protein [4]. In this study, to clarify the ac-
tions of benzbromarone on PPARs, the aﬃnity of benzbro-
marone for PPARα and PPARγ w a sr e e x a m i n e di nc o m -
parison with a representative activator of each receptor. In
addition, regarding the mechanism of gene expression in-
duced by benzbromarone, binding between PPARs and per-
oxisome proliferator-responsive element (PPRE), and pro-
tein expressions of lipoprotein lipase (LPL), and acyl-CoA
synthetase (ACS) encoded by the target gene of PPAR were
examined.2 PPAR Research
Based on the ﬁndings, hepatic hypertrophy due to benz-
bromarone and the inﬂuence of benzbromarone on lipid
metabolism are discussed.
2. MATERIALS AND METHODS
2.1. Chemicals
Benzbromarone, an active pharmaceutical ingredient of Uri-
norm marketed by Torii Pharmaceutical Co., Ltd. (Tokyo,
Japan), was used as a test compound in this study. Trogli-
tazone, pioglitazone and fenoﬁbric acid were synthesized at
the Central Research Pharmaceutical Institute of Japan To-
baccoInc.(Osaka,Japan).Cloﬁbric acid waspurchasedfrom
Sigma-Aldrich Japan (Tokyo, Japan), nuclear and cytoplas-
mic extraction reagents from Pierce (Ill, USA), and a nucleic
acid labeling kit from Molecular Probes (Ore, USA).
2.2. Cellculture
NIH/3T3cellsandhumankidney293Tcellsweremaintained
in D-MEM containing 10% fetal bovine serum, 50U/mL
penicillin and 50μg/mL streptomycin at 37◦C in a humidi-
ﬁed 95% air and 5% CO2 atmosphere.
2.3. Reportergeneanalysis
NIH/3T3 cells (0.4 × 105 cells/well) were cultured in 24-well
plates for 20 hours and then transfected with a receptor plas-
mid for the chimera of PPARγ or the PPARα ligand-binding
domain and GAL4 DNA-binding domain, together with a
receptor plasmid containing the GAL4-responsive promoter
driving expression of luciferase. After 6 hours, cells were
given fresh D-MEM containing test compounds at ﬁnal con-
centrations of 0.001–100μM, and were cultured for an ad-
ditional 2 days. Benzbromarone, cloﬁbric acid, fenoﬁbric
acid, troglitazone, and pioglitazone were suspended in 0.1%
DMSO solution. After cells had been lysed, luciferase activity
wasdeterminedusingaCT-9000Dluminometer(Dia-iatron,
Tokyo, Japan).
Atotalof3measurementswereperformedforeachbatch
ofculturedcellspertest,andatotalof3testswereperformed.
2.4. Electricmobilityshiftassay(EMSA)
First, following addition of benzbromarone at a ﬁnal con-
centration of 1μM, 293T cells were cultured for 24 hours.
Cells were washed with TBS and pelleted by centrifugation at
1500×g for 5 minutes. Pellets were suspended in 1mL TBS
and transferred into an Eppendorf tube, then centrifuged
again at 1000×g for 5 minutes to obtain pellets. Double-
stranded oligonucleotides for sequences of the PPRE and
mutant of PPRE were purchased from Santa Cruz Biotech-
nology (Calif, USA). Oligonucleotides were labeled with
Alexa Flour 488 using a ULYSIS Nucleic Acid Labeling Kit
(Molecular Probes). Labeled oligonucleotides (500ng) were
added to nuclear extracts. The binding assay buﬀer com-
prised 20mM HEPES (pH 7.5) containing 40mM KCl, 5%
glycerol, and 1μg dl-dC. Assay was performed at room tem-
perature for 10 minutes at a ﬁnal volume of 25μL. Products
ofthebindingreactionwereseparatedon5%polyacrylamide
gel run in Tris-borate-EDTA at room temperature at 100V
for 60 minutes. Gels were visualized using a Fluorimager
SI (Molecular Dynamics, Tokyo, Japan). This test was per-
formed 6 times.
2.5. Westernblotanalysis
Benzbromarone was added to 293T cells to achieve a ﬁnal
concentration of 1 or 10μM, and cells were cultured for 24
hours. Western blots for LPL and ACS proteins were then
performed according to established procedures. Brieﬂy, af-
ter cells (108 cells/well) had been suspended in lysis buﬀer
(10mM sodium phosphate, 150mM NaCl, 0.5% sodium
deoxycholate, 0.1% SDS, 100μg/mL PMSF, 30μg/mL apro-
tinin, and 1mM sodium orthovanadate, pH 7.4), aliquots
of the cell suspension were obtained by repetitive pipet-
ting and lysed by incubation at 4◦C for 15 minutes. Lysed
cells were centrifuged at 400×g for 10 minutes, and the su-
pernatant was separated by SDS-polyacrylamide gel elec-
trophoresis in 10% acrylamide gel. The protein was trans-
ferred onto a nitrocellulose membrane and blocked for 60
minutes. The membrane was then incubated with anti-ACS
(Japan Ram, Tokyo, Japan) or anti-LPL (Daiichi Pure Chem-
icals,Tokyo,Japan)antibodies.Afterwashing,themembrane
was incubated with horseradish peroxidase-conjugated anti-
rabbit secondary antibodies (The Binding Site, Birmingham,
UK). Chemiluminescence of bound antibodies was detected
using a kit (Amersham BioSciences, NJ, USA). Protein con-
tents were determined by the generally established method
of Lowry using BSA as a standard. This test was performed 4
times.
3. RESULTS
The binding aﬃnity of benzbromarone for PPARα and
PPARγ was examined by reporter gene assay using tran-
scriptional activity of the PPAR target gene as a marker,
in comparison with those of cloﬁbric acid, fenoﬁbric acid,
troglitazone, and pioglitazone (Figures 1 and 2). At 100μM,
benzbromarone induced an increase in luciferase activity,
representing transcriptional activation of the target gene via
bindingofbenzbromaronetoPPARα,andthemagnitudewas
nearlyequaltothatinducedbycloﬁbricacid,whilefenoﬁbric
acid and pioglitazone induced transcriptional activation of
thetargetgeneatconcentrationsof ≥ 10μM.AgainstPPARγ,
benzbromarone induced an increase in luciferase activity at a
concentration of 100μM, troglitazone at ≥ 1μM, and piogli-
tazone at ≥ 0.1μM.
After adding benzbromarone to 293T cells, the nu-
clear extract was incubated with ﬂuorescence-labeled PPRE
oligonucleotide, and binding activity between PPARs and
PPRE was determined by EMSA. Binding between PPARs
and PPRE increased in cells with benzbromarone as com-
pared to cells without benzbromarone (Figure 3). In addi-
tion,whenmutantPPREoligonucleotidewasincubatedwith
PPARs, no evidence of binding was found.
After addition of benzbromarone to 293T cells at ﬁnal
concentrations of 1μMa n d1 0 μM, LPL and ACS proteinChiyoko Kunishima et al. 3
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Figure 1: Eﬀects of benzbromarone (•), troglitazone (◦), pioglita-
zone (), fenoﬁbric acid (), and cloﬁbric acid (Δ)o nP P A R α ac-
tivation. Cells were transfected with the receptor plasmid for the
chimera of the PPARα ligand-binding domain and GAL4 DNA-
binding domain, together with a reporter plasmid containing a
GAL4-responsive promoter driving the expression of luciferase.
Each point represents mean ± standard deviation (SD).
expressions were determined using the western blot method,
demonstrating a dose-dependent increase in each protein
(Figure 4).
4. DISCUSSION
PPAR regulates transcriptional activation of the target gene
by forming a heterodimer with the retinoid X receptor, and
recognizingandbindingtoPPREviaaspeciﬁcgenesequence
[5].VariousproteinssuchasLPL,ACS,fattyacidtransporter,
and fatty acid binding protein have been reported to be ex-
pressedasaresultoftranscriptionalactivationoftargetgenes
by PPARs [6–8].
CloﬁbrateandfenoﬁbrateasPPARα activatorsandtrogli-
tazone and pioglitazone as PPARγ activators are considered
to aﬀect the metabolism of lipids and carbohydrates in the
living body through these processes [9–11]. The present
studies were performed to elucidate the details of PPAR acti-
vation by benzbromarone, which has been shown to induce
hepatic hypertrophy associated with peroxisomal prolifera-
tion in rats [2].
First, the ligand aﬃnity of benzbromarone for PPARα
was equivalent to that of cloﬁbric acid, a representative ac-
tivator of PPARα. The aﬃnity of benzbromarone for PPARγ
was weak and clearly inferior to the aﬃnities of troglita-
zone and pioglitazone, which are representative activators of
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Figure 2: Eﬀects of benzbromarone (•), troglitazone (◦), piogli-
tazone (), fenoﬁbric acid () ,a n dc l o ﬁ b r i ca c i d( Δ)o nP P A R γ
activation. Cells were transfected using the receptor plasmid for
the chimera of the PPARγ ligand-binding domain and GAL4 DNA-
binding domain, together with a reporter plasmid containing a
GAL4-responsive promoter driving the expression of luciferase.
Each point represents mean ± SD.
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Figure 3: Comparative analysis of PPARs DNA-labeled PPRE com-
plex by EMSA in nuclear extracts of 293T cells with or without
benzbromarone treatment for 24 hours. Presence of PPRE was ver-
iﬁed by incubation with mutant PPRE oligonucleotide.
PPARγ. Second, benzbromarone added to 293T cells elicited
an increase in speciﬁc binding between PPARs and PPRE.
Third, benzbromarone enhanced protein expression of LPL
and ACS in a concentration-dependent manner.
In addition, the last experiment revealed more marked
enhancement of PPARα expression than PPARγ expres-
sion by benzbromarone [4]. Moreover, based on the re-
sults of in vitro and in vivo expression analyses of various4 PPAR Research
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Figure 4: Expression levels of (a) LPL protein and (b) ACS pro-
tein as determined by Western blot analysis in 293T cells with or
without benzbromarone treatment for 24 hours. The optimal den-
sity for each band measured using NIH Image. 1.6 is as follows: (a)
LPL protein: 64.14 (0μM), 98.16 (1μM), 113.37 (10μM). (b) ACS
protein: 51.05 (0μM), 63.29 (1μM), 94.66 (10μM).
PPARα-regulated genes in rats, benzbromarone has recently
been classiﬁed as a PPARα agonist [12, 13]. The present ﬁnd-
ings support these reports from the perspective of intracellu-
lar gene transcription.
In patients receiving benzbromarone and in those re-
ceiving troglitazone, pioglitazone, cloﬁbrate, fenoﬁbrate,
or other PPARs activators, hepatic impairment with an
undeniable causal relationship to these drugs has been re-
ported [14–17].
On the basis of the above ﬁndings and taking into
account the mechanisms underlying increases in PPAR-
mediatedgeneexpressionbyPPARα activatorssuchascloﬁb-
ric acid and fenoﬁbric acid and PPARγ activators such as
troglitazone and pioglitazone, we concluded that benzbro-
marone can be classiﬁed as a PPARα activator. The hepatic
hypertrophy caused by benzbromarone in rats may thus be
inducedviaenhancementofPPARα-mediatedtargetgeneex-
pression and the resultant changes in lipid metabolism. In
this context, the newly elucidated pharmacological features
of benzbromarone could provide some hints that benzbro-
marone and other PPAR activators might display common
mechanisms with relation to hepatic adverse eﬀects.
The present study demonstrated that benzbromarone, a
uricosuric drug, displays aﬃnity for PPARs despite having
ad i ﬀerent chemical structure from ﬁbrate-class antihyper-
lipemic drugs (fenoﬁbrate, cloﬁbrate) and thiazolidine-class
antidiabetic drugs (troglitazone, pioglitazone), by compari-
son to these PPAR activators.
Considering that Cmax following oral administration of
100mg benzbromarone in humans is approximately 5μM
[18], which is lower than levels in the present study, the
present in vitro results may be diﬃcult to simply extrapolate
to clinical use. However, further investigations must be care-
fully conducted using the present ﬁndings as reference, into
the relationships between benzbromarone and glucose and
lipid metabolism, to reconﬁrm the clinical value of benzbro-
marone.
ABBREVIATIONS
ACS: Acyl-CoA synthetase
EMSA: Electric mobility shift assay
LPL: Lipoprotein lipase
PPARα: Peroxisome proliferator-activated receptor α
PPARγ: Peroxisome proliferator-activated receptor γ
PPRE: Peroxisome proliferator-responsive element
URAT1: Urate transporter 1
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